PMID- 31352198
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 12
IP  - 10
DP  - 2019 Oct
TI  - Emerging Pathogenic and Prognostic Significance of Paired Box 3 (PAX3) Protein in 
      Adult Gliomas.
PG  - 1357-1363
LID - S1936-5233(19)30340-7 [pii]
LID - 10.1016/j.tranon.2019.07.001 [doi]
AB  - Gliomas present the most common type of brain tumors in adults, characterized by 
      high morbidity and mortality. In search of potential molecular targets, members 
      of paired box (PAX) family have been found expressed in neural crest cells, 
      regulating their proliferation, apoptosis, migration and differentiation. 
      Recently, PAX3 overexpression has been implicated in glioma tumorigenesis by 
      enhancing proliferation, increasing invasiveness and inducing resistance to 
      apoptosis of glioma cells, while maintaining brain glioma stem cells (BGSCs) 
      stemness. Although the oncogenic potential of PAX3 in gliomas is still under 
      investigation, experimental evidence suggests that PAX3 function is mainly 
      mediated through the canonical and non-canonical Wnt signaling pathway as well as 
      through its interaction with GFAP and p53 proteins. In addition, PAX3 may 
      contribute to the chemoresistance of glioma cells and modulates the effectiveness 
      of novel experimental therapies. Further evidence indicates that PAX3 may 
      represent a novel diagnostic and prognostic biomarker for gliomas, facilitating 
      personalized treatment. This review addresses the emerging role of PAX3 in glioma 
      diagnosis, prognosis and treatment, aiming to shed more light on the underlying 
      molecular mechanisms that could lead to more effective treatment approaches.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Angelopoulou, Efthalia
AU  - Angelopoulou E
AD  - Department of Biological Chemistry, Medical School, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Paudel, Yam Nath
AU  - Paudel YN
AD  - Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and 
      Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
FAU - Piperi, Christina
AU  - Piperi C
AD  - Department of Biological Chemistry, Medical School, National and Kapodistrian 
      University of Athens, Athens, Greece. Electronic address: cpiperi@med.uoa.gr.
LA  - eng
PT  - Journal Article
DEP - 20190725
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC6664158
EDAT- 2019/07/29 06:00
MHDA- 2019/07/29 06:01
PMCR- 2019/07/25
CRDT- 2019/07/29 06:00
PHST- 2019/07/02 00:00 [received]
PHST- 2019/07/08 00:00 [accepted]
PHST- 2019/07/29 06:00 [pubmed]
PHST- 2019/07/29 06:01 [medline]
PHST- 2019/07/29 06:00 [entrez]
PHST- 2019/07/25 00:00 [pmc-release]
AID - S1936-5233(19)30340-7 [pii]
AID - 10.1016/j.tranon.2019.07.001 [doi]
PST - ppublish
SO  - Transl Oncol. 2019 Oct;12(10):1357-1363. doi: 10.1016/j.tranon.2019.07.001. Epub 
      2019 Jul 25.